Navigation Links
Mast Therapeutics Announces Positive Data In Model Of Heart Failure
Date:1/6/2014

potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of any planned phase 2 clinical study of MST-188; the uncertainty of outcomes in ongoing and future studies of MST-188 and the risk that MST-188 may not demonstrate adequate safety, efficacy or tolerability in one or more such studies; the potential that, even if clinical studies of MST-188 in one indication are successful, clinical studies in another indication may not be successful; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the Company's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of MST-188, including clinical studies, and regulatory activities for MST-188, and that such third parties may fail to perform as expected; the Company's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner MST-188 at inopportune times or pursue less expensive but higher-risk and/or lower return development paths if it is unable to raise sufficient additional capital as needed; the risk that, even if the Company successfully develops MST-188 in one or more indications, it may not realize commercial success with its products and may never generate revenue sufficient to achieve profitability; the risk that the Company is not able to adequately protect its intellectual property rights relating to the MAST platform and MST-188 and prevent competitors from duplicating or developing equivalent versions of its product candidates, including MST-188; and other risks and uncertainties more fully described in
'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Tasly Pharmaceuticals, Inc., ... modernize medicine, announced today the launch of Deepure. ... developed to address men and women concerned with ... vibrant into old age while helping keep their ... condition-specific, whole-food and herb-based formulas, namely, ProHeart PLUS, ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the markets ... , Russia , ... (BRIC) will see robust expansion as these economies expand ... procedures. Although revenues will be somewhat impeded by poor ... approval times and demand for low-cost products, the market ...
(Date:9/30/2014)... 2014   Easy Breathe , the fastest growing ... that it now offers the revolutionary AirSense ... first sleep apnea therapy devices with internal cellular modems.  ... track and share real-time data on each user,s quality ... therapy.  In addition, the internal modem allows the CPAP ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... American Oriental Bioengineering, Inc. (NYSE: AOB ... dedicated to improving healthcare through the development, manufacture ... and over-the-counter ("OTC") products, today announced that its ... and Chief Financial Officer, Ms. Lily Li were ...
... Jan. 25, 2011 Reportlinker.com announces that ... in its catalogue: Brand ... small molecule brand erosion post-patent expiry ... IntroductionPharma is facing slowing sales growth ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2Reportlinker Adds Brand Erosion Post-Patent Expiry - An analysis of small molecule brand erosion post-patent expiry 2
(Date:10/1/2014)... 01, 2014 Insuranceragents.info has released ... good life insurance plan for vulnerable family members. , ... family members. Providers in the family should always carry ... financial hardships for the rest of the family. ... Families can benefit more from temporary coverage or from ...
(Date:10/1/2014)... Hillsboro, Oregon (PRWEB) October 01, 2014 ... curing solutions , continues to expand the business worldwide. ... engineering along with additional capacity for manufacturing efforts. The ... over the last five years and expects this growth ... UV LED curing technology gains worldwide adoption. , ...
(Date:10/1/2014)... N.C. A new genetic finding from Duke Medicine ... anxiety and depression might also be hard-wired to gain ... and heart disease. , An estimated 13 percent of ... genetic susceptibility, and knowing this could help them reduce ... diet, exercise and stress management. , "Genetic susceptibility, psychosocial ...
(Date:10/1/2014)... 2014 Diet Doc understands that many of ... weight and their dieting attempts could be easily sabotaged by ... hormone diet treatments into their programs as a way ... fast and effective weight loss results, it also allows patients ... to maintain their weight for the future. , Earlier versions ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was ... Martha Stewart American Made Awards (MSAMAs), an annual competition ... in the fields of crafts, design, food and style. ... finalist in the MSAMAs, which celebrates entrepreneurs and artisans ... local communities and changing the way we shop, work ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
... findings reported at symposium on gastrointestinal cancers , , THURSDAY, ... zeroed in on a biomarker that could detect colorectal ... invasive and more accurate way than existing blood tests. ... also differentiate between early- and late-stage disease, the researchers ...
... ZYTO Corp. (Pink Sheets:,ZYTC) has announced the appointment of ... Howard as C.F.O., The internal appointments come as ... Dr. Vaughn R. Cook, company founder, president and,C.E.O. Howard ... the,financial responsibilities., Howard joined ZYTO in April of ...
... is a,statement by Blue Shield of California CEO Bruce Bodaken ... universal coverage, I,m disappointed that we,did not clear this hurdle ... make perfection the enemy of the good. This bill should ... We have waited too long to make health coverage for ...
... Jan. 23 InterMune, Inc.,(Nasdaq: ITMN ) today ... InterMune, will present at the 2008 Wachovia Healthcare,Conference in ... To access a live audio webcast of the ... the investor relations page of InterMune,s,corporate website at ...
... RARITAN, N.J., Jan. 23 Johnson & Johnson,Pharmaceutical ... a New Drug Application (NDA) to the U.S. ... release (IR),tablets, an investigational oral analgesic for the ... to the American Pain Foundation, more than 25 ...
... treatments to blame, study finds , , WEDNESDAY, Jan. 23 ... to treat people with peripheral arterial disease (PAD) than ... finds. , Both PAD (blocked abdomen and leg arteries) ... same methods, including medication, surgery and endovascular techniques such ...
Cached Medicine News:Health News:New Colon Cancer Test Might Spot Trouble Earlier 2Health News:New Colon Cancer Test Might Spot Trouble Earlier 3Health News:ZYTO Corp. Appoints New Chief Operations Officer and New Chief Financial Officer 2Health News:InterMune to Present at the 2008 Wachovia Healthcare Conference 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 3Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 4Health News:Peripheral Arterial Disease Costlier to Treat Than Heart Trouble 2
Inquire...
Microseal 'F' foil, seals plates for cold storage (or cycling >25l), disposable, pkg of 100...
Sterilization: sterilized Yes...
Effective adhesive, may be removed from plate without residue. Transparent film for easy visual monitoring of samples...
Medicine Products: